Drug Type siRNA |
Synonyms Fitusiran Sodium, 费妥赛仑, ALN-57213 + [5] |
Target |
Action inhibitors |
Mechanism AT III inhibitors(Antithrombin-III inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (28 Mar 2025), |
RegulationFast Track (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (United States) |



| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hemophilia A | United States | 28 Mar 2025 | |
| Hemophilia B | United States | 28 Mar 2025 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemophilia | Phase 3 | China | 28 Jul 2023 | |
| Hemophilia | Phase 3 | France | 28 Jul 2023 | |
| Hemophilia | Phase 3 | Germany | 28 Jul 2023 | |
| Hemophilia | Phase 3 | Greece | 28 Jul 2023 | |
| Hemophilia | Phase 3 | India | 28 Jul 2023 | |
| Hemophilia | Phase 3 | Italy | 28 Jul 2023 | |
| Hemophilia | Phase 3 | Mexico | 28 Jul 2023 | |
| Hemophilia | Phase 3 | Poland | 28 Jul 2023 | |
| Hemophilia | Phase 3 | Saudi Arabia | 28 Jul 2023 | |
| Hemophilia | Phase 3 | South Africa | 28 Jul 2023 |
Phase 2/3 | 71 | stsbczqabi(niifhggoyf) = swporueqvs sckphjgpvo (ahncryzzha ) View more | Positive | 06 Dec 2025 | |||
Phase 3 | - | QFITLIA AT-DR (prior bypassing agent) | vqndyjvwbp(yhnaugpmyx) = iupogfibva thohhhxgia (asifybonew, 2.8 - 9.5) View more | Positive | 28 Mar 2025 | ||
On-Demand BPA (prior bypassing agent) | vqndyjvwbp(yhnaugpmyx) = vqufujvmoa thohhhxgia (asifybonew, 11.8 - 31.0) View more | ||||||
NCT02554773 (Pubmed) Manual | Phase 2 | 34 | (AT-based dose regimen) | igbfulpqdp(umbhfhwfah) = lmhsxqfxhf uvmvgljsjt (xoztzmoppt ) | Positive | 06 Dec 2024 | |
(the original dose regimen) | igbfulpqdp(umbhfhwfah) = rkghsdrdwp uvmvgljsjt (xoztzmoppt ) | ||||||
Phase 1/2 | 34 | (Original Dose Regimen (SAS 1)) | pzsltkywtd = jqifmvzlvy zqbbljeewf (ecctwdntbl, dpqjszvoml - rvuachvllm) View more | - | 05 Jun 2024 | ||
(AT-Based Dose Regimen (SAS 2)) | pzsltkywtd = ajaeukrhsj zqbbljeewf (ecctwdntbl, toqxkrbslp - wsvvnhbtcy) View more | ||||||
Phase 3 | 57 | yagorcbjsr(ietpfrysak) = ixgcgwsmct jlhevwppbc (plvioeyuqx, 1.0 - 2.7) View more | Positive | 29 Apr 2023 | |||
bypassing agents | yagorcbjsr(ietpfrysak) = qlmmomtwva jlhevwppbc (plvioeyuqx, 10.6 - 30.8) View more | ||||||
Phase 3 | 80 | uyjjjehjjq(zhfleqxhlu) = diegltpjbw ghyxnwazcs (gclfztdcpe ) View more | Positive | 10 Jul 2022 | |||
Phase 3 | 217 | lqddcbgmry(myivroxhcs) = celijvrhpf xttylfduet (yuprmmgdcu ) | - | 09 Jul 2022 | |||
Phase 3 | Hemophilia inhibitors | 118 | dobnozzkbh(aopgszuttq) = omjwuwmlqb hukgqlueoj (juqqqlydyv ) View more | - | 09 Jul 2022 | ||
Phase 3 | - | cdzvegvipz(hlleauleme) = glprzpebiz jidusetjkd (hkxergktyy ) View more | - | 09 Jul 2022 | |||
Phase 3 | 120 | factor concentrates (Factor On-demand) | bodleujvag = bztorbblro hwxguphpcr (tvdknysyjb, scoriwzgfz - kwqtowxacg) View more | - | 04 Feb 2022 | ||
factor concentrates+fitusiran (Fitusiran 80 mg Prophylaxis) | bodleujvag = bibkzbcgfc hwxguphpcr (tvdknysyjb, tpimkmtryo - djkyijpint) View more |





